GIAPREZA (Angiotensin Ii Acetate) Patent Expiration, LOE Window & CMS Spending

GIAPREZA (Angiotensin Ii Acetate) by La Jolla: FDA Orange Book LOE 2037-01-06, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLa Jolla
FDA Application & PathwayN209360 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-01-06
Orange Book Patents (*PED Extensions)45 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 26.6% 2-yr change)